semaglutide approved Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients The FDA has approved the

previously controlled hypertension that suddenly becomes difficult to manage without changes in antihypertensive medication

35 Similarly, in a recent study of obese individuals without diabetes, Louis et al demonstrated that tirzepatide (10 or 15 mg) resulted in significantly greater weight loss than semaglutide (1.7 or 2.4 mg) over a 72-week period

A number of drugs prescribed to lower ICP (particularly acetazolamide and topiramate in IIH) compromise cognitive function

For healthcare professionals, patients, and researchers, these resources offer a starting point for further exploration into the optimal management of these therapies, highlighting the ongoing need for research, education, and interdisciplinary collaboration to navigate the complexities of modern pharmacotherapy

GLP-1 long-term side effects that happen rarely are the following: Allergic reactions

Your provider will review your weight history, BMI, medical conditions, medications, previous weight loss attempts, and long-term goals before making treatment recommendations